

INTRABIOTICS PHARMACEUTICALS INC /DE  
Form SC 13G/A  
February 26, 2003

=====  
SEC 1745 (6-01) Potential persons who are to respond to the collection of  
information contained in this form are not required to respond unless the form  
displays a currently valid OMB control number.  
=====

-----  
OMB APPROVAL  
-----

OMB Number 3235-0145  
Expires: October 31, 2002  
Estimated average burden  
hours per response ..... 14.90  
-----

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934  
(Amendment No. 3)\*

INTRABIOTICS PHARMACEUTICALS, INC.

-----  
(Name of Issuer)

Common Stock, \$.001 par value

-----  
(Title of Class of Securities)

46116T 10 0

-----  
(CUSIP Number)

December 31, 2002

-----  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule  
is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's  
initial filing on this form with respect to the subject class of securities, and  
for any subsequent amendment containing information which would alter the  
disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed  
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13G/A

1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 8 pages

CUSIP No. 46116T 10 0

13G

Page 2 of 8 Pages

---

1. Name of Reporting Persons  
I.R.S. Identification Nos. of above persons (entities only)  
Tang Capital Partners, LP

---

2. Check the Appropriate Box If a Member of a Group (See Instructions)  
(a)   
(b)  Joint-Filing

---

3. SEC Use Only

---

4. Citizenship or Place of Organization  
United States

---

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	5. Sole Voting Power
	1,251,900
	6. Shared Voting Power
	0
7. Sole Dispositive Power	
1,251,900	
8. Shared Dispositive Power	
0	

---

9. Aggregate Amount Beneficially Owned by Each Reporting Person  
1,251,900

---

10. Check Box If the Aggregate Amount in Row (9) Excludes Certain Shares  
(See Instructions)

---

11. Percent of Class Represented by Amount in Row (9)  
3.3%

---

12. Type of Reporting Person (See Instructions)  
PN

---

CUSIP No. 46116T 10 0

13G

Page 3 of 8 Pages

---

1. Name of Reporting Persons  
I.R.S. Identification Nos. of above persons (entities only)  
Tang Capital Management, LLC

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13G/A

---

2. Check the Appropriate Box If a Member of a Group (See Instructions)

- (a)   
(b)  Joint-Filing

---

3. SEC Use Only

---

4. Citizenship or Place of Organization  
United States

---

NUMBER OF SHARES	5. Sole Voting Power 1,251,900
BENEFICIALLY OWNED BY EACH	6. Shared Voting Power 0
REPORTING PERSON WITH:	7. Sole Dispositive Power 1,251,900
	8. Shared Dispositive Power 0

---

9. Aggregate Amount Beneficially Owned by Each Reporting Person  
1,251,900

---

10. Check Box If the Aggregate Amount in Row (9) Excludes Certain Shares  
(See Instructions)

---

11. Percent of Class Represented by Amount in Row (9)  
3.3%

---

12. Type of Reporting Person (See Instructions)  
OO

---

CUSIP No. 46116T 10 0

13G

Page 4 of 8 Pages

---

1. Name of Reporting Persons

I.R.S. Identification Nos. of above persons (entities only)  
Kevin C. Tang

---

2. Check the Appropriate Box If a Member of a Group (See Instructions)

- (a)   
(b)  Joint-Filing

---

3. SEC Use Only

---

4. Citizenship or Place of Organization  
United States

---

NUMBER OF SHARES	5. Sole Voting Power 1,251,900
BENEFICIALLY OWNED BY	6. Shared Voting Power 0

---

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13G/A

EACH  
REPORTING PERSON WITH:  
7. Sole Dispositive Power  
1,251,900  
8. Shared Dispositive Power  
0

9. Aggregate Amount Beneficially Owned by Each Reporting Person  
1,251,900

10. Check Box If the Aggregate Amount in Row (9) Excludes Certain Shares  
(See Instructions)

11. Percent of Class Represented by Amount in Row (9)  
3.3%

12. Type of Reporting Person (See Instructions)  
IN

CUSIP No. 46116T 10 0

13G

Page 5 of 8 Pages

1. Name of Reporting Persons  
I.R.S. Identification Nos. of above persons (entities only)  
Oscar L. Tang

2. Check the Appropriate Box If a Member of a Group (See Instructions)  
(a)   
(b)  Joint-Filing

3. SEC Use Only

4. Citizenship or Place of Organization  
United States

NUMBER OF SHARES  
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:  
5. Sole Voting Power  
281,000  
6. Shared Voting Power  
114,500  
7. Sole Dispositive Power  
281,000  
8. Shared Dispositive Power  
114,500

9. Aggregate Amount Beneficially Owned by Each Reporting Person  
395,500

10. Check Box If the Aggregate Amount in Row (9) Excludes Certain Shares  
(See Instructions)

11. Percent of Class Represented by Amount in Row (9)  
1.0%

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13G/A

12. Type of Reporting Person (See Instructions)  
IN

---

Item 1(a). Name of Issuer: Intrabiotics Pharmaceuticals, Inc.

---

Item 1(b). Address of Issuer's Principal Executive Offices:  
1245 Terra Bella Avenue, Mountain View, CA 94043

---

Item 2(a). Name of Person Filing:  
Tang Capital Partners, LP  
Tang Capital Management, LLC  
Kevin C. Tang  
Oscar L. Tang

---

Item 2(b). Address of Principal Business Office, or if None, Residence:  
Tang Capital Partners, LP  
Tang Capital Management, LLC  
Kevin C. Tang  
4401 Eastgate Mall  
San Diego, CA 92121  
  
Oscar L. Tang  
c/o Reich & Tang Asset Management LLC  
600 Fifth Avenue, 8th Floor  
New York, NY 10020

---

Item 2(c). Citizenship: United States

---

Item 2(d). Title of Class of Securities: Common Stock, par value \$.001

---

Item 2(e). CUSIP Number: 46116T 10 0

---

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b) OR  
240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

- (a)  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
- (b)  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c)  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d)  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e)  An investment adviser in accordance with ss.240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13G/A

ss.240.13d-1(b)(1)(ii)(F);

- (g)  A parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G);
- (h)  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).

Not applicable.

ITEM 4. OWNERSHIP.

- (a) Amount beneficially owned as of December 31, 2002:  
The aggregate number and percentage of securities to which this Schedule 13G relates is 1,647,400 shares, representing 4.3% of the 37,784,886 shares outstanding as reported by the Issuer in its Form 10Q filed with the SEC on November 14, 2002. The Filing Persons beneficially own those securities set forth below:

Tang Capital Partners, LP	1,251,900 shares
Tang Capital Management, LLC	1,251,900 shares
Kevin C. Tang	1,251,900 shares
Oscar L. Tang	395,500 shares

- (b) Percent of class:

Tang Capital Partners, LP	3.3%
Tang Capital Management, LLC	3.3%
Kevin C. Tang	3.3%
Oscar L. Tang	1.0%

- (c) Number of shares as to which such person has:

- (i) Sole power to vote or to direct the vote:

Tang Capital Partners, LP	1,251,900 shares
Tang Capital Management, LLC	1,251,900 shares
Kevin C. Tang	1,251,900 shares
Oscar L. Tang	281,000 shares

- (ii) Shared power to vote or to direct the vote:

Tang Capital Partners, LP	0 shares
Tang Capital Management, LLC	0 shares
Kevin C. Tang	0 shares
Oscar L. Tang	114,500 shares

- (iii) Sole power to dispose or to direct the disposition of:

Tang Capital Partners, LP	1,251,900 shares
Tang Capital Management, LLC	1,251,900 shares
Kevin C. Tang	1,251,900 shares
Oscar L. Tang	281,000 shares

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13G/A

(iv) Shared power to dispose or to direct the disposition of:

Tang Capital Partners, LP	0 shares
Tang Capital Management, LLC	0 shares
Kevin C. Tang	0 shares
Oscar L. Tang	114,500 shares

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:  
NOT APPLICABLE

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY: NOT APPLICABLE

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:  
See Item 12 of Cover Pages and Item 2 of this Amendment No. 3 to Schedule 13G. Tang Capital Partners, LP is the registered holder of the shares. Tang Capital Management, LLC is the general partner of Tang Capital Partners, LP. Kevin C. Tang is the Manager of Tang Capital Management, LLC. Kevin C. Tang is the son of Oscar L. Tang.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP  
Not applicable.

ITEM 10. CERTIFICATION

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 25, 2002

-----  
(Date)

TANG CAPITAL PARTNERS, LP  
By: Tang Capital Management, LLC

By: /s/ Kevin C. Tang

-----  
Kevin C. Tang, Manager

TANG CAPITAL MANAGEMENT, LLC

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13G/A

By: /s/ Kevin C. Tang  
-----  
Kevin C. Tang, Manager

/s/ Kevin C. Tang  
-----  
KEVIN C. TANG

/s/ Oscar L. Tang  
-----  
OSCAR L. TANG

EXHIBIT I  
TO  
AMENDMENT NO. 3  
TO  
SCHEDULE 13G  
UNDER THE  
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Pursuant to Rule 13d-1(k)(1), TANG CAPITAL PARTNERS, LP affirms that it is individually eligible to use Schedule 13G and agrees that this Schedule is filed on its behalf.

TANG CAPITAL PARTNERS, LP  
By: Tang Capital Management, LLC  
  
By: /s/ Kevin C. Tang  
-----  
Kevin C. Tang, Manager

EXHIBIT II  
TO  
AMENDMENT NO. 3  
TO



Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13G/A

SCHEDULE 13G

UNDER THE

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Pursuant to Rule 13d-1(k)(1), TANG CAPITAL MANAGEMENT, LLC affirms that it is individually eligible to use Schedule 13G and agrees that this Schedule is filed on its behalf.

TANG CAPITAL MANAGEMENT, LLC

By: /s/ Kevin C. Tang

-----  
Kevin C. Tang, Manager

EXHIBIT III

TO

AMENDMENT NO. 3

TO

SCHEDULE 13G

UNDER THE

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Pursuant to Rule 13d-1(k)(1), KEVIN C. TANG affirms that it is individually eligible to use Schedule 13G and agrees that this Schedule is filed on its behalf.

/s/ Kevin C. Tang

-----  
Kevin C. Tang

EXHIBIT IV

TO

AMENDMENT NO. 3

TO

SCHEDULE 13G

UNDER THE

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13G/A

Pursuant to Rule 13d-1(k)(1), OSCAR L. TANG affirms that it is individually eligible to use Schedule 13G and agrees that this Schedule is filed on its behalf.

/s/ Oscar L. Tang

-----  
Oscar L. Tang